Rgenix Gains $40 Million in Series C Funding
October 9, 2018
2:33 pm
Rgenix, Inc., a clinical stage biopharmaceutical company developing small molecule and antibody cancer therapeutics, raised $40 million in a Series C financing round led by Lepu Medical, a publicly traded global healthcare firm, Oceanpine Capital, and WuXi AppTec’s Corporate Venture Fund. Existing investors Novo Holdings